A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E/K Mutant Melanoma
Sponsor: SWOG
Protocol number: S1320
Projected enrollment dates: February 2015 to December 2016
Official study title: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E/K Mutant Melanoma
ClinicalTrials.gov page:
http://www.clinicaltrials.gov/show/NCT02196181